Revumenib as an epigenetic treatment for pulmonary arterial hypertension
Official title: Investigating Revumenib for Targeted Epigenetic Therapy in Pulmonary Arterial Hypertension
Funded at Icahn School of Medicine at Mount Sinai · NIH-11338930 · Data updated 2026-11-12
This project looks at whether the drug revumenib can reverse harmful cell changes that narrow lung arteries in people with pulmonary arterial hypertension.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 1, 2026 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $462,000 |
| NIH project number | 1R21TR006197-01 |
| Project ID | NIH-11338930 on NIH RePORTER |
Who could benefit from this research
✓Could help
People diagnosed with pulmonary arterial hypertension, especially those whose disease continues to progress despite current therapies, would be the most relevant candidates.
✕Less likely to help
Patients with other types of pulmonary hypertension (for example due to left heart disease or lung disease) or those with very advanced, irreversible right heart failure may not benefit from this approach.
What this research studies
From a patient's point of view, researchers will study how revumenib affects the behavior of pulmonary artery smooth muscle cells that become overly active and resist normal cell death. They will examine whether the drug can change key epigenetic marks (chemical tags on genes) that drive this harmful cell behavior. Experiments will use lab-grown human cells and animal models to see if revumenib reduces vascular remodeling and pressure in the lungs. Findings will guide whether this approach could move toward human testing in the future.
Why it matters
Potential benefit: If successful, this approach could slow or reverse artery narrowing in the lungs, potentially easing symptoms and lowering the risk of right heart failure.
How similar studies have gone: Menin inhibitors like revumenib have shown promise in certain blood cancers and preclinical models for changing disease-driving gene expression, but using them in PAH is a new and largely untested idea.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Hadri, Lahouaria — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hadri, Lahouaria
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.